Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.

Gridelli C, Maione P, Rossi A, De Marinis F.

Oncologist. 2007 Oct;12(10):1183-93. Review.

2.

Recent developments of targeted therapies in the treatment of non-small cell lung cancer.

Rossi A, Maione P, Colantuoni G, Ferrara C, Rossi E, Guerriero C, Nicolella D, Falanga M, Palazzolo G, Gridelli C.

Curr Drug Discov Technol. 2009 Jun;6(2):91-102. Review.

PMID:
19519336
3.

New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.

Manegold C.

Clin Lung Cancer. 2008;9 Suppl 3:S100-8. doi: 10.3816/CLC.2008.s.015. Review.

PMID:
19419923
4.

Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.

Rossi A, Maione P, Ferrara ML, Sacco PC, Schettino C, Bareschino MA, Gridelli C.

Curr Med Chem. 2009;16(30):3919-30. Review.

PMID:
19747132
5.

Bevacizumab in non-small cell lung cancer.

Di Costanzo F, Mazzoni F, Micol Mela M, Antonuzzo L, Checcacci D, Saggese M, Di Costanzo F.

Drugs. 2008;68(6):737-46. Review.

PMID:
18416583
6.

Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.

Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P, Grossi F.

Crit Rev Oncol Hematol. 2008 Dec;68(3):183-96. doi: 10.1016/j.critrevonc.2008.05.002. Epub 2008 Jul 7. Review.

PMID:
18606548
7.

Role of bevacizumab for the treatment of non-small-cell lung cancer.

Ramalingam S, Belani CP.

Future Oncol. 2007 Apr;3(2):131-9. Review.

PMID:
17381412
8.

Angiogenesis inhibition in the treatment of lung cancer.

Vokes E, Herbst R, Sandler A.

Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 23):1-10; quiz 11-2. Review.

PMID:
17143257
9.

The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Langer CJ, Natale RB.

Semin Oncol. 2005 Dec;32(6 Suppl 10):S23-9. Review.

PMID:
16459176
10.

Bevacizumab for the treatment of advanced non-small-cell lung cancer.

Manegold C.

Expert Rev Anticancer Ther. 2008 May;8(5):689-99. doi: 10.1586/14737140.8.5.689. Review.

PMID:
18471042
11.

Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC).

Schmid-Bindert G.

Target Oncol. 2013 Mar;8(1):15-26. doi: 10.1007/s11523-013-0261-1. Epub 2013 Feb 1. Review.

PMID:
23371029
12.

Bevacizumab in non small cell lung cancer.

Sandler A.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4613-6. Review.

13.

The potential of antiangiogenic therapy in non-small cell lung cancer.

Giaccone G.

Clin Cancer Res. 2007 Apr 1;13(7):1961-70. Review.

14.

New insights in drug development for the non-small cell lung cancer therapy.

Gridelli C, Rossi A, Maione P, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D, Palazzolo G, Falanga M, Colantuoni G.

Front Biosci. 2008 May 1;13:5108-19. Review.

PMID:
18508573
15.

Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.

Sandler AB, Johnson DH, Herbst RS.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4258s-4262s. Review.

16.

New antiangiogenetic agents and non-small cell lung cancer.

Gridelli C, Rossi A, Maione P.

Crit Rev Oncol Hematol. 2006 Oct;60(1):76-86. Epub 2006 Jul 13. Review.

PMID:
16843002
17.

[Targeted therapies in the treatment of non-small cell lung cancer].

De Grève J, Decoster L, Van Meerbeek J, Vermeij J, Teugels E, Schallier D.

Bull Cancer. 2008 Mar;95(3):358-64. doi: 10.1684/bdc.2008.0591. Review. French.

18.
19.

The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.

Langer C, Soria JC.

Clin Lung Cancer. 2010 Mar 1;11(2):82-90. doi: 10.3816/CLC.2010.n.011. Review.

PMID:
20199973
20.

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.

Cabebe E, Wakelee H.

Curr Treat Options Oncol. 2007 Feb;8(1):15-27. Review.

PMID:
17634832

Supplemental Content

Support Center